Biogen sets pricing for new MS drug

04/1/2013 | Yahoo

Biogen Idec said it would price its newly approved multiple sclerosis drug Tecfidera at $54,900 annually, lower than those of rivals including Novartis' Gilenya but higher than analysts had forecast. "We think this represents solid value to the MS community and demonstrates our commitment to patient access," Biogen spokeswoman Kate Niazi-Sai said.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC